Abdallah Mohammad, Lin Lihuan, Styles Ian K, Mörsdorf Alexander, Grace James L, Gracia Gracia, Landersdorfer Cornelia B, Nowell Cameron J, Quinn John F, Whittaker Michael R, Trevaskis Natalie L
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
J Control Release. 2024 May;369:146-162. doi: 10.1016/j.jconrel.2024.03.032. Epub 2024 Mar 26.
Delivery to peripheral lymphatics can be achieved following interstitial administration of nano-sized delivery systems (nanoparticles, liposomes, dendrimers etc) or molecules that hitchhike on endogenous nano-sized carriers (such as albumin). The published work concerning the hitchhiking approach has mostly focussed on the lymphatic uptake of vaccines conjugated directly to albumin binding moieties (ABMs such as lipids, Evans blue dye derivatives or peptides) and their subsequent trafficking into draining lymph nodes. The mechanisms underpinning access and transport of these constructs into lymph fluid, including potential interaction with other endogenous nanocarriers such as lipoproteins, have largely been ignored. Recently, we described a series of brush polyethylene glycol (PEG) polymers containing end terminal short-chain or medium-chain hydrocarbon tails (1C2 or 1C12, respectively), cholesterol moiety (Cho), or medium-chain or long-chain diacylglycerols (2C12 or 2C18, respectively). We evaluated the association of these materials with albumin and lipoprotein in rat plasma, and their intravenous (IV) and subcutaneous (SC) pharmacokinetic profiles. Here we fully detail the association of this suite of polymers with albumin and lipoproteins in rat lymph, which is expected to facilitate lymph transport of the materials from the SC injection site. Additionally, we characterise the thoracic lymph uptake, tissue and lymph node biodistribution of the lipidated brush PEG polymers following SC administration to thoracic lymph cannulated rats. All polymers had moderate lymphatic uptake in rats following SC dosing with the lymph uptake higher for 1C2-PEG, 2C12-PEG and 2C18-PEG (5.8%, 5.9% and 6.7% dose in lymph, respectively) compared with 1C12-PEG and Cho-PEG (both 1.5% dose in lymph). The enhanced lymph uptake of 1C2-PEG, 2C12-PEG and 2C18-PEG appeared related to their association profile with different lipoproteins. The five polymers displayed different biodistribution patterns in major organs and tissues in mice. All polymers reached immune cells deep within the inguinal lymph nodes of mice following SC dosing. The ability to access these immune cells suggests the potential of the polymers as platforms for the delivery of vaccines and immunotherapies. Future studies will focus on evaluating the lymphatic targeting and therapeutic potential of drug or vaccine-loaded polymers in pre-clinical disease models.
在间质内给予纳米级递送系统(纳米颗粒、脂质体、树枝状大分子等)或搭附于内源性纳米级载体(如白蛋白)上的分子后,可实现向周围淋巴管的递送。已发表的关于搭附方法的研究大多集中在直接与白蛋白结合部分(如脂质、伊文思蓝染料衍生物或肽等白蛋白结合分子)偶联的疫苗的淋巴摄取及其随后向引流淋巴结的转运。这些构建体进入淋巴液的途径和运输机制,包括与其他内源性纳米载体(如脂蛋白)的潜在相互作用,在很大程度上被忽视了。最近,我们描述了一系列含有末端短链或中链烃尾(分别为1C2或1C12)、胆固醇部分(Cho)或中链或长链二酰甘油(分别为2C12或2C18)的刷状聚乙二醇(PEG)聚合物。我们评估了这些材料与大鼠血浆中白蛋白和脂蛋白的结合情况,以及它们的静脉内(IV)和皮下(SC)药代动力学特征。在此,我们详细阐述了这组聚合物与大鼠淋巴中白蛋白和脂蛋白的结合情况,这有望促进材料从皮下注射部位向淋巴的转运。此外,我们对脂质化刷状PEG聚合物在给胸导管插管大鼠皮下给药后的胸淋巴摄取、组织和淋巴结生物分布进行了表征。所有聚合物在大鼠皮下给药后均有适度的淋巴摄取,与1C12 - PEG和Cho - PEG(两者在淋巴中的剂量均为1.5%)相比,1C2 - PEG、2C12 - PEG和2C18 - PEG的淋巴摄取更高(分别为淋巴中剂量的5.8%、5.9%和6.7%)。1C2 - PEG、2C12 - PEG和2C18 - PEG增强的淋巴摄取似乎与其与不同脂蛋白的结合情况有关。这五种聚合物在小鼠的主要器官和组织中表现出不同的生物分布模式。所有聚合物在皮下给药后均到达小鼠腹股沟淋巴结深处的免疫细胞。进入这些免疫细胞的能力表明这些聚合物作为疫苗和免疫疗法递送平台的潜力。未来的研究将集中在评估载药或载疫苗聚合物在临床前疾病模型中的淋巴靶向性和治疗潜力。